“We believe this approach can be applied to other cancer markers and bodily fluids to greatly improve clinical performance and ultimately, patient management. We are pleased to have Tony serve as a speaker and panel chair, given the Company’s record of innovation and technology leadership.”

In a presentation entitled, “A Cost Effective Assay for Multiplexing Protein and DNA Biomarkers on a Single Analytical Platform,” Anthony P. Shuber, chief technology officer, will discuss the company’s use of next generation sequencing to simultaneously detect protein and DNA biomarkers on one analytical platform. The method developed can eliminate the need to perform separate procedures for protein and DNA while decreasing assay complexity and cost. Mr. Shuber will also chair a technical session at the meeting on tips and tricks for the application of next generation sequencing on Tuesday, August 14 at 9:30 a.m. (EST).

The Company recently launched a sequencing-based version of its CertNDx Bladder Cancer Assay which uses a NGS sequencing platform to detect FGFR3 mutations that are indicative of bladder cancer. “We are very excited about the progress we have made applying next generation sequencing to clinical diagnostics,” said Marc Schneebaum, chief executive officer. “We believe this approach can be applied to other cancer markers and bodily fluids to greatly improve clinical performance and ultimately, patient management. We are pleased to have Tony serve as a speaker and panel chair, given the Company’s record of innovation and technology leadership.”

Mr. Shuber will also be presenting “Incorporating Next-Gen Sequencing into the Clinical Environment” at the upcoming Next Generation Dx Summit in Washington, DC on Tuesday, August 21 at 3:20 p.m. (EST). The presentation will focus on the recently developed assay that uses NGS to detect single mutant molecules of FGFR3 in urine. The assay performance resulted in mutation detection in urine that is >90% concordant with that found in tissue.

About Predictive Biosciences

Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. For additional information, please visit www.predictivebiosci.com.